BIOGEN INC.
BIIBPharma & biotechbiogen.com
Latest available resultsSeptember 30, 2026Quarter · 10-Q filed Oct 28, 2026
Next reportFebruary 4, 2027after close · forecast 2.901 $/share
Revenue
$2.80B
▲ +10.6% vs prior year YoY
Net income
−$20.60M
▼ -104.4% vs prior year YoY
EPS
-0.14$
▼ -104.4% vs prior year YoY
Net margin
-0.7%
▼ -19.1 pp vs prior year YoY
Revenue▲ +10.6%
Margins (% of revenue)GrossOperating N/ANet
Net income▼ -104.4%
EPS▼ -104.4%
Financial statements
View 10-Q filed October 28, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $2.45B | $2.43B | $2.65B | $2.53B | $2.28B | $2.48B | $2.74B | $2.80B | ▲ +10.6% |
| Gross profit | $1.87B | $1.80B | $2.04B | $1.86B | $1.78B | $1.82B | $1.96B | $2.06B | ▲ +10.5% |
| Operating income | — | — | — | — | — | — | — | — | — |
| Net income | $266.70M | $240.50M | $634.80M | $466.50M | −$48.90M | $319.50M | $97.50M | −$20.60M | ▼ -104.4% |
| R&D | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | — | 1.64 $ | 4.33 $ | 3.17 $ | — | 2.15 $ | 0.66 $ | -0.14 $ | ▼ -104.4% |
| Margins (% of revenue) | |||||||||
| Gross | 76.2 % | 74.1 % | 77.1 % | 73.4 % | 78.3 % | 73.3 % | 71.6 % | 73.3 % | ▼ -0.1 pt |
| Operating | — | — | — | — | — | — | — | — | — |
| Net | 10.9 % | 9.9 % | 24.0 % | 18.4 % | -2.1 % | 12.9 % | 3.6 % | -0.7 % | ▼ -19.1 pt |
| Balance sheet | |||||||||
| Assets | $28.05B | $28.03B | $28.33B | $29.21B | $29.44B | $29.48B | $32.09B | $32.05B | ▲ +9.7% |
| Liabilities | $11.33B | $11.05B | $10.70B | $11.00B | $11.18B | $10.83B | $13.24B | $13.13B | ▲ +19.4% |
| Equity | $16.72B | $16.98B | $17.63B | $18.21B | $18.26B | $18.65B | $18.85B | $18.92B | ▲ +3.9% |
| Cash | — | — | — | — | — | — | — | — | — |
| Capital | |||||||||
| Shares outstanding | 146.37M | 146.53M | 146.61M | 146.70M | 146.76M | 147.64M | 147.75M | 147.82M | ▲ +0.8% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.